Rubicon Research’s wholly owned unit, Advagen Holdings, entered a definitive agreement with GEnE Lifesciences Inc. to acquire Series Prime Preferred Stock in tranches for a total value of up to $3 million, according to the company’s exchange filing.
Source: Rubicon Research Limited Press Release (NSE Exchange Filings) | Published on Oct 21, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Rubicon Research Ltd (NSE Exchange Filings), the company announced that its wholly owned subsidiary, Advagen Holdings Inc., has entered into a definitive agreement with GEnE Lifesciences Inc.
Under this agreement, Advagen Holdings will acquire Series Prime Preferred Stock of GEnE Lifesciences in multiple tranches for a total consideration of up to $3 million. The agreement formalises an equity investment arrangement between the two entities.
The announcement was disclosed to the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) at 15:15 hours IST on 23 October 2025, following the execution of the signed documents.
Also read: Federal Bank Clarifies No Decision on 9.99% Preferential Issue
Advagen Holdings, a wholly owned subsidiary of Rubicon Research, has signed a definitive agreement with GEnE Lifesciences Inc.
The acquisition involves Series Prime Preferred Stock valued at up to $3 million, to be completed in tranches.
Disclosure made to BSE and NSE at 15:15 hours IST on 23 October 2025.
The agreement complies with applicable disclosure and investment regulations.
Also read: Dr Reddy’s Labs Gets US FDA EIR Classified as VAI for Srikakulam Facility
The transaction outlines Advagen Holdings’ plan to acquire Series Prime Preferred Stock through phased capital investment. The tranches will be structured in accordance with the agreed milestones and compliance conditions between the companies.
The disclosure clarifies that the consideration of up to $3 million represents the maximum investment value agreed upon under the definitive terms. Each tranche will be executed based on completion and verification of specific deliverables as set out in the agreement.
All regulatory and procedural requirements applicable to such acquisitions will be completed in line with relevant laws and exchange disclosure norms.
Rubicon Research Ltd is a pharmaceutical company engaged in product development, manufacturing, and technology-driven formulation research. Its wholly owned subsidiary, Advagen Holdings Inc., operates as an investment and holding entity for Rubicon’s overseas ventures.
GEnE Lifesciences Inc., the counterparty in the agreement, is engaged in life sciences research and development, with operations focused on specialised biotechnology applications.
At the time of disclosure, Rubicon Research’s share price on the National Stock Exchange (NSE) stood at ₹612.50, marking a 0.57% increase as of 15:30 PM IST on 21 October 2025.
Parameter | Detail |
Parent Company | Rubicon Research Ltd |
Subsidiary | Advagen Holdings Inc. |
Counterparty | GEnE Lifesciences Inc. |
Transaction Type | Acquisition of Series Prime Preferred Stock |
Total Consideration | Up to USD 3 million |
Mode of Acquisition | Tranches |
Disclosure Time | 15:15 hours IST, 23 October 2025 |
Stock Exchange | NSE / BSE |
Rubicon Research Share Price | ₹612.50 |
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates companies to promptly report any event or information that could be material for investors.
Also read: NMDC Revises Iron Ore Pricing; Baila Lump ₹5,550 & Fines ₹4,750
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading